Dr. Andrés Cervantes Ruipérez

Investigador Principal
Grupo de Investigación en cáncer colorrectal y nuevos desarrollos terapéuticos en tumores sólidos

Presentación

El Dr. Andrés Cervantes es director científico del Instituto de Investigación Sanitaria INCLIVA, donde, además, coordina el Área de Investigación en Cáncer. Asimismo, es jefe del Servicio de Oncología Médica del Hospital Clínico Universitario de València y catedrático de Medicina de la Universitat de València.

Centra su investigación en neoplasias gastrointestinales y en el desarrollo de tratamientos innovadores para el cáncer. Sus últimos estudios se focalizan en el papel de la biopsia líquida como herramienta de medicina de precisión en oncología. Entiende la investigación como un servicio a la sociedad para que, mejorando la comprensión y solución de problemas de salud, sea posible garantizar un futuro mejor.

Es responsable de proyectos de investigación financiados por el Instituto de Salud Carlos III, del Ministerio de Sanidad, y por la Unión Europea, así como por otras entidades públicas y privadas.

Está particularmente implicado en la formación de nuevos especialistas y de jóvenes investigadores clínicos que faciliten la conexión entre ciencia y conocimiento hasta la atención sanitaria. Ha dirigido más de 15 tesis doctorales y es autor de más de 500 publicaciones científicas en revistas internacionales indexadas. Ha sido incluido en la lista de investigadores más citados del año 2021, de Clarivate Analitics.

Es autor principal de las Guías de Práctica Clínica para el cáncer colorrectal avanzado (2022) y coautor de las Guías de cáncer esofágico de la Sociedad Europea de Oncología Médica (ESMO). Es editor jefe de la revista Cancer Treatment Reviews y editor asociado de Annals of Oncology.

Ha sido elegido presidente de ESMO para el periodo 2023-2024. ESMO es una sociedad global que agrupa a más de 27.000 profesionales del ámbito de la oncología distribuidos por todo el mundo. Sus áreas de actuación son la educación de los profesionales sanitarios, la difusión del conocimiento científico entre sus miembros y la promoción de políticas públicas que faciliten la equidad y sostenibilidad de los tratamientos contra el cáncer en el ámbito europeo e internacional.

Dr. Andrés Cervantes Ruipérez
Investigador
Principal
Dr. Andrés Cervantes Ruipérez

andres.cervantes@uv.es

Publicaciones
Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, Sharma S, Renner D, Hafez D, Roda D, Huerta M, Rosello S, Madsen AH, Love US, Andersen PV, Thorlacius-Ussing O, Iversen LH, Gotschalck KA, Sethi H, Aleshin A, Cervantes A, Andersen CL. Clinical Cancer Research. 2022 Feb 1;28(3):507-517. doi: 10.1158/1078-0432.CCR-21-2404. PMID: 34625408

Clinical management of metastatic colorectal cancer in the era of precision medicine. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. CA-A Cancer Journal for Clinicians. 2022 Apr 26. doi: 10.3322/caac.21728. PMID: 35472088

Colorectal cancer survival: prevalence of psychosocial distress and unmet supportive care needs. Andreu Y, Martinez P, Soto-Rubio A, Fernandez S, Bosch C, Cervantes A. Supportive Care in Cancer. 2022 Feb;30(2):1483-1491. doi: 10.1007/s00520-021-06513-1. PMID: 34529142

Corrigendum to «Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up»: [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2022 Jun;33(6):666. doi: 10.1016/j.annonc.2022.03.009. PMID: 35365377

ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski R, Curigliano G, Felip E, Ferreira A, Ganz P, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge A, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni G. Annals of Oncology. 2022 Aug 10;S0923-7534(22)03792-9. doi: 10.1016/j.annonc.2022.07.1941. PMID: 35963481

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. Italiano A, Cassier PA, Lin C, Alanko T, Peltola KJ, Gazzah A, Shiah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V. Cancer Immunology Immunotherapy. 2022 Feb;71(2):417-431. doi: 10.1007/s00262-021-02973-w. PMID: 34216247

First-in-human phase I Study of the OX40 agonist MOXR0916 in patients with advanced solid tumors. Kim T, Burris H, de Miguel Luken M, Pishvaian M, Bang Y, Gordon M, Awada A, Camidge D, Hodi F, McArthur G, Miller W, Cervantes A, Chow L, Lesokhin A, Rutten A, Sznol M, Rishipathak D, Chen S, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu L. Clinical Cancer Research. 2022 Aug 15;28(16):3452-3463. doi: 10.1158/1078-0432.CCR-21-4020. PMID: 35699599

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T’jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. Cancer Chemotherapy and Pharmacology. 2022 Apr;89(4):499-514. doi: 10.1007/s00280-022-04414-6. PMID: 35298698

Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty COVID-19 vaccine in nursing home residents. Albert E, Burgos JS, Peiro S, Salas D, Vanaclocha H, Gimenez E, Limon R, Alcaraz MJ, Sanchez-Paya J, Diez-Domingo J, Cervantes A, Navarro D. Clinical Microbiology and Infection. 2022 Feb;28(2):279-284. doi: 10.1016/j.cmi.2021.09.031. PMID: 34619398

In the literature: April 2022. Ciardiello D, Roda D, Gambardella V, Cervantes A. ESMO Open. 2022 Apr 23;7(3):100479. doi: 10.1016/j.esmoop.2022.100479. PMID: 35472677

In the literature: December 2021. Montagut C, Gambardella V, Cabeza-Segura M, Fleitas T, Cervantes A. ESMO Open. 2022 Feb;7(1):100352. doi: 10.1016/j.esmoop.2021.100352. PMID: 34920292

In the literature: February 2022. Gambardella V, Cejalvo JM, Gonzalez Barrallo I, Gimeno Valiente F, Cervantes A. ESMO open. 2022 Feb 23;7(2):100411. doi: 10.1016/j.esmoop.2022.100411. PMID: 35219243

In the literature: July 2022. Gambardella V, Martinelli E, Tarazona N, Cervantes A. ESMO Open. 2022 Aug;7(4):100556. doi: 10.1016/j.esmoop.2022.100556. PMID: 35961192

Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcon-Molero L, Gonzalez-Vilanova A, Zuniga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Dura A, Richart P, Alonso N, Huerta M, Rosello S, Roda D, Tarazona N, Martinez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. British Journal of Cancer. 2022 Oct 17. doi: 10.1038/s41416-022-02005-z. PMID: 36253523

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. PMID: 35914638

Paclitaxel induces epidermal molecular changes and produces subclinical alterations in the skin of gynecological cancer patients. Montero P, Perez-Leal M, Perez-Fidalgo JA, Sanz C, Estornut C, Roger I, Milara J, Cervantes A, Cortijo J. Cancers. 2022 Feb 23;14(5):1146. doi: 10.3390/cancers14051146. PMID: 35267454

Quality of life in cancer survivorship: Sociodemographic and disease-related moderators. Andreu Y, Martinez P, Soto-Rubio A, Perez-Marin M, Cervantes A, Arribas L. European Journal of Cancer Care. 2022 Sep 7;e13692. doi: 10.1111/ecc.13692. PMID: 36069249

SMG8/SMG9 heterodimer loss modulates SMG1 kinase to drive ATR inhibitor resistance. Llorca-Cardenosa MJ, Aronson LI, Krastev DB, Nieminuszczy J, Alexander J, Song F, Dylewska M, Broderick R, Brough R, Zimmermann A, Zenke FT, Gurel B, Riisnaes R, Ferreira A, Roumeliotis T, Choudhary J, Pettitt SJ, de Bono J, Cervantes A, Haider S, Niedzwiedz W, Lord CJ, Chong IY. Cancer Research. 2022 Oct 23;OF1-OF12. doi: 10.1158/0008-5472.CAN-21-4339. PMID: 36273494

SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, Gonzalez B, Arance A, Martin-Liberal J, Gavila J, Lopez-Gonzalez A, Miguel Cejalvo J, Izarzugaza Y, Amillano K, Garcia Corbacho J, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesia R, Cervantes A, Tabernero J. Future Oncology. 2022 Oct 6. doi: 10.2217/fon-2022-0660. PMID: 36200668

Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: a multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Kroese TE, van Rossum PSN, Nilsson M, Lordick F, Smyth EC, Rosati R, Nafteux P, D’Ugo D, Chaudry MA, Polkowkski W, Roviello F, Gockel I, Kolodziejczyk P, Haustermans K, Guckenberger M, Nordsmark M, Hawkins MA, Cervantes A, Fleitas T, van Cutsem E, Moehler M, Wagner AD, van Laarhoven HWM, van Hillegersberg R. European Journal of Surgical Oncology. 2022 Sep 24;S0748-7983(22)00682-5. doi: 10.1016/j.ejso.2022.09.012. PMID: 36184420

The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. Van Schooten T, Derks S, Jimenez-Marti E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O’Connor J, Esteso F, Farres J, Mas J, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T. BMC Cancer. 2022 Jun 13;22(1):646. doi: 10.1186/s12885-022-09689-9. PMID: 35692051

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. Castelo-Branco L, Awada A, Pentheroudakis G, Perez-Gracia J, Mateo J, Curigliano G, Banerjee S, Giuliani R, Lordick F, Cervantes A, Tabernero J, Peters S. ESMO Open. 2021 Jul 24;6(5):100237. doi: 10.1016/j.esmoop.2021.100237. PMID: 34411971

Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervello C, Garces-Albir M, Cervantes A, Ibarrola-Villava M. Cancers. 2021 Feb 27;13(5):994. doi: 10.3390/cancers13050994. PMID: 33673558

Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. Pavlidis N, Peccatori F, Aapro M, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Journal of Cancer Education. 2021 Oct;36(5):1124-1128. doi: 10.1007/s13187-020-01744-y. PMID: 32303982

Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Gambardella V, Martinez-Ciarpaglini C, Fleitas T, Cervantes A. ESMO Open. 2021 Nov 6;6(6):100285. doi: 10.1016/j.esmoop.2021.100285. PMID: 34752996

Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer. Gimeno-Valiente F, Riffo-Campos A, Torres L, Tarazona N, Gambardella V, Cervantes A, Lopez-Rodas G, Franco L, Castillo J. Cancers. 2021 Mar 21;13(6):1433. doi: 10.3390/cancers13061433. PMID: 33801071

ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. Annals of Oncology. 2021 Jul;32(7):823-824. doi: 10.1016/j.annonc.2021.04.001. PMID: 34090547

ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. ESMO open. 2021 Jun;6(3):100130. doi: 10.1016/j.esmoop.2021.100130. PMID: 34144776

ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. Pavlidis N, Peccatori F, Aapro M, Eniu A, Stahel R, Cervantes A, Cavalli F, Costa A. Journal of Cancer Education. 2021 Jun;36(3):556-560. doi: 10.1007/s13187-019-01664-6. PMID: 31845109

First-in-human phase I study of a next-generation, oral, transforming growth factor-beta receptor 1 inhibitor, LY3200882 in patients with advanced cancer. Yap TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Lohr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. Clinical Cancer Research. 2021 Dec 15;27(24):6666-6676. doi: 10.1158/1078-0432.CCR-21-1504. PMID: 34548321

First-line biological agents plus chemotherapy in older patients with metastatic colorectal cancer: a retrospective pooled analysis. Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales M, Mozo J, Munoz A, Duran G, Sastre J, Safont M, Ferreiro R, Rivera F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, Alonso-Orduna V, Vieitez J, Yubero A, Aranda E, Spanish Cooperative Grp Treatment. Drugs & Aging. 2021 Mar;38(3):219-231. doi: 10.1007/s40266-021-00834-w. PMID: 33615402

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Lo Cascio A, Gandini S, Lizier M, Braga D, Asnicar F, Segata N, Klaver C, Brescia P, Rossi E, Anselmo A, Guglietta S, Maroli A, Spaggiari P, Tarazona N, Cervantes A, Marsoni S, Lazzari L, Jodice M, Giovanna L, Chiara E, Marco PS, Di Fiore PP, Viale G, Spinelli A, Pozzi C, Penna G, Rescigno M. Cancer Cell. 2021 May 10;39(5):708-724.e11. doi: 10.1016/j.ccell.2021.03.004. PMID: 33798472

In the literature: April 2021. Martin-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo J M, Cervantes A. ESMO open. 2021 Apr 19;6(3):100116. doi: 10.1016/j.esmoop.2021.100116. PMID: 33887688

In the literature: August 2021. Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, Cervantes A. ESMO Open. 2021 Aug 16;6(5):100247. doi: 10.1016/j.esmoop.2021.100247. PMID: 34411970

In the literature: December 2020. Gambardella V, Ibarrola-Villaba M, Tarazona N, Cervantes A. ESMO Open. 2021 Jan 4;6(1):100009. doi: 10.1016/j.esmoop.2020.100009. PMID: 33399075

In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. ESMO Open. 2021 Feb 24;6(2):100061. doi: 10.1016/j.esmoop.2021.100061. PMID: 33639602

In the literature: June 2021. Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. ESMO open. 2021 Jun;6(3):100186. doi: 10.1016/j.esmoop.2021.100186. PMID: 34098228

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Martinez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, Martinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa S, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta M, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. British Journal of Cancer. 2021 Oct;125(9):1261-1269. doi: 10.1038/s41416-021-01502-x. PMID: 34493820

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti B, Ahn J, Faud I, Chee C, Yeh K, Lin P, Chua C, Hasbullah H, Lee M, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Annals of Oncology. 2021 Dec;32(12):1496-1510. doi: 10.1016/j.annonc.2021.08.1752. PMID: 34411693

Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders. Pellino G, Garcia-Granero E, Cervantes A. European Journal of Surgical Oncology. 2021 Oct;47(10):2697. doi: 10.1016/j.ejso.2021.06.031. PMID: 34217579

Radiomics and radiogenomics in head and neck squamous cell carcinoma: potential contribution to patient management and challenges. Bruixola G, Remacha E, Jimenez-Pastor A, Dualde D, Viala A, Monton J, Ibarrola-Villava M, Alberich-Bayarri A, Cervantes A. Cancer Treatment Reviews. 2021 Sep;99:102263. doi: 10.1016/j.ctrv.2021.102263. PMID: 34343892

Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 Sep;32(9):1190-1191. doi: 10.1016/j.annonc.2021.05.795. PMID: 34033882

Retrospective study of regorafenib versus TAS-102 efficacy and safety in chemorefractory Metastatic Colorectal Cancer (mCRC) patients: a multi-institution real life clinical data. Vitale P, Zanaletti N, Famiglietti V, De Falco V, Cervantes A, Rosellò S, Fenocchio E, Milanesio M, Lombardi P, Ciardiello D, Martini G, Martinelli E, Ciardiello F, Troiani T, Napolitano S. Clinical Colorectal Cancer. 2021 Sep;20(3):227-235. doi: 10.1016/j.clcc.2021.06.002. PMID: 34226142

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer R, Dijkstra E, van Etten B, Marijnen C, Putter H, Kranenbarg E, Roodvoets A, Nagtegaal I, Beets-Tan R, Blomqvist L, Fokstuen T, Ten Tije A, Capdevila J, Hendriks M, Edhemovic I, Cervantes A, Nilsson P, Glimelius B, van de Velde C, Hospers G, RAPIDO collaborative investigators. Lancet. Oncology. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. PMID: 33301740

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. Malhi V, Budha N, Sane R, Huang J, Liederer B, Meng R, Patel P, Deng Y, Cervantes A, Tabernero J, Musib L. Cancer Chemotherapy and Pharmacology. 2021 Dec;88(6):921-930. doi: 10.1007/s00280-021-04344-9. PMID: 34471960

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. Martinez MT, Monton-Bueno J, Simon S, Ortega B, Moragon S, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. ESMO open. 2021 May 11;6(3):100148. doi: 10.1016/j.esmoop.2021.100148. PMID: 33989988

The COVID-19 pandemic could be a setback for gender equality in oncology-and a key moment to push ahead with transformative policies. Cervantes A. ESMO Open. 2021 Jun;6(3):100169. doi: 10.1016/j.esmoop.2021.100169. PMID: 34144777

Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project. Pellino G, Alós R, Biondo S, Codina-Cazador A, Enríquez-Navascues J, Espín-Basany E, Roig-Vila J, Cervantes Ruiperez A, Carceller R, Spanish Rectal Cancer Project collaborators. EJSO. 2021 Feb;47(2):276-284. doi: 10.1016/j.ejso.2020.04.056. PMID: 32950316

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Vogel A, Martinelli E, ESMO Guidelines Commite. Annals of Oncology. 2021 Jun;32(6):801-805. doi: 10.1016/j.annonc.2021.02.014. PMID: 33716105

A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. Delord J, Argiles G, Fayette J, Wirth L, Kasper S, Siena S, Mesia R, Berardi R, Cervantes Ruiperez A, Dekervel J, Zhao S, Sun Y, Hao H, Tiedt R, Vicente S, Myers A, Siu L. Investigational New Drugs. 2020 Dec;38(6):1774-1783. doi: 10.1007/s10637-020-00928-z. PMID: 32410080

Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer. Smyth E, Cervantes Ruiperez A. ESMO Open. 2020 Nov;5(6):e001107. doi: 10.1136/esmoopen-2020-001107. PMID: 33208490

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. Isakoff S, Tabernero J, Molife L, Soria J, Cervantes Ruiperez A, Vogelzang N, Patel M, Hussain M, Baron A, Argiles G, Conkling R, Sampath D, Maslyar D, Patel P, Chan W, Gendreau S, Musib L, Xu N, Ma H, Lin K, Bendell J. Annals of Oncology. 2020 May;31(5):626-633. doi: 10.1016/j.annonc.2020.02.007. PMID: 32205017

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer A Secondary Analysis of the AVANT Trial. Chibaudel B, Henriques J, Rakez M, Brenner B, Kim Tae Won, Martinez Villacampa M, Gallego Plazas J, Cervantes A, Shim K, Jonker D, Guerin Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, Andre T, de Gramont A. Jama Network Open. 2020 Oct 1;3(10):e2020425. doi: 10.1001/jamanetworkopen.2020.20425. PMID: 33074326

Aurora kinases in ovarian cancer. Perez Fidalgo J, Gambardella V, Pineda Merlo B, Burgues Gasion O, Piñero Sanchez O, Cervantes Ruiperez A. ESMO Open. 2020 Oct;5(5):e000718. doi: 10.1136/esmoopen-2020-000718. PMID: 33087400

Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. Pavlidis N, Peccatori F, Aapro M, Rolfo C, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Critical Reviews in Oncology Hematology. 2020 Feb;146:102798. doi: 10.1016/j.critrevonc.2019.07.022. PMID: 31918958

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial (vol 147, pg 75, 2020). van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, de Groot Derk JA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP. Radiotherapy and Oncology. 2020 Jun;147:e1. doi: 10.1016/j.radonc.2020.06.006. PMID: 32564889

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial. van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, de Groot DJA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP. Radiotherapy and Oncology. 2020 Jun;147:75-83. doi: 10.1016/j.radonc.2020.03.011. PMID: 32240909

Computational evaluation and in vitro validation of new Epidermal Growth Factor Receptor inhibitors. Gomez-Ganau S, Castillo Aliaga J, Cervantes Ruiperez A, de Julian Ortiz J, Gozalbes R. Current Topics in Medicinal Chemistry. 2020;20(18):1628-1639. doi: 10.2174/1568026620666200603122726. PMID: 32493189

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. Tarazona Llavero N, Gimeno Valiente F, Gambardella V, Huerta Alvaro M, Roselló Keränen S, Zúñiga Trejos S, Calon A, Carbonell Asins J, Fontana E, Martínez Ciarpaglini M, Eason K, Rentero Garrido P, Fleitas Kanonnikoff T, Papaccio F, Moro Valdezate D, Nyamundanda G, Castillo Aliaga J, Espí Macias A, Sadanandam A, Roda Perez D, Cervantes Ruiperez A. ESMO Open. 2020 Sep;5(5):e000847. doi: 10.1136/esmoopen-2020-000847. PMID: 32967918

Editorial debate: Challenges we oncologists, working within a universal healthcare system, have to face in these hard times. Cervantes Ruiperez A. ESMO Open. 2020 May;5(3):e000800. doi: 10.1136/esmoopen-2020-000800. PMID: 32366509

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Smyth L, Piha-Paul S, Won H, Schram A, Saura C, Loi S, Lu J, Shapiro G, Juric D, Mayer I, Arteaga C, de la Fuente M, Brufksy A, Spanggaard I, Mau-Sorensen M, Arnedos M, Moreno V, Boni V, Sohn J, Schwartzberg L, Gonzalez-Farre X, Cervantes Ruiperez A, Bidard F, Gorelick A, Lanman R, Nagy R, Ulaner G, Chandarlapaty S, Jhaveri K, Gavrila E, Zimel C, Selcuklu S, Melcer M, Samoila A, Cai Y, Scaltriti M, Mann G, Xu F, Eli L, Dujka M, Lalani A, Bryce R, Baselga J, Taylor B, Solit D, Meric-Bernstam F, Hyman D. Cancer Discovery. 2020 Feb;10(2):198-213. doi: 10.1158/2159-8290.CD-19-0966. PMID: 31806627

EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. Gimeno Valiente F, Riffo Campos Á, Ayala Gallego G, Tarazona Llavero N, Gambardella V, Rodriguez F, Huerta Alvaro M, Martínez Ciarpaglini M, Monton Bueno J, Roselló Keränen S, Roda Perez D, Cervantes Ruiperez A, Franco Vera L, Lopez Rodas G, Castillo Aliaga J. Scientific Reports. 2020 Feb 28;10(1):3723. doi: 10.1038/s41598-020-60476-7. PMID: 32111877

How we treat metastatic colorectal cancer. De Falco V, Napolitano S, Rosello S, Huerta M, Cervantes A, Ciardiello F, Troiani T. ESMO Open. 2020 Aug;4(Suppl 2):e000813. doi: 10.1136/esmoopen-2020-000813. PMID: 32817137

Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. Baguena G, Pellino G, Frasson M, Escrig J, Marinello F, Espí Macias A, Garcia-Granero A, Roselló Keränen S, Cervantes Ruiperez A, Garcia-Granero E. Gastroenterologia y Hepatologia. 2020 Feb;43(2):63-72. doi: 10.1016/j.gastrohep.2019.07.005. PMID: 31918857

In the literature: April 2020. Gambardella V, Roda D, Tarazona N, Cervantes A. ESMO Open. 2020 Apr;5(2):e000749. doi: 10.1136/esmoopen-2020-000749. PMID: 32317263

In the literature: August 2020. Gambardella V, Cejalvo J, Tarazona N, Cervantes A. ESMO Open. 2020 Aug;5(4):e000909. doi: 10.1136/esmoopen-2020-000909. PMID: 32817070

In the literature: December 2019. Gambardella V, Insa A, Cejalvo J, Cervantes A. ESMO Open. 2020 Jan;5(1):e000642. doi: 10.1136/esmoopen-2019-000642. PMID: 31958287

In the literature: February 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. ESMO Open. 2020 Feb;5(1):e000680. doi: 10.1136/esmoopen-2020-000680. PMID: 32079625

In the literature: June 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. ESMO Open. 2020 Jul;5(4):e000832. doi: 10.1136/esmoopen-2020-000832. PMID: 32641355

In the literature: October 2020. Gambardella V, Bruixola Campos G, Alfaro Cervelló C, Cervantes Ruiperez A. ESMO Open. 2020 Oct;5(5):e001048. doi: 10.1136/esmoopen-2020-001048. PMID: 33037034

JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Yoshino T, Pentheroudakis G, Mishima S, Overman M, Yeh K, Baba E, Naito Y, Calvo F, Saxena A, Chen L, Takeda M, Cervantes Ruiperez A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard J. Annals of Oncology. 2020 Jul;31(7):861-872. doi: 10.1016/j.annonc.2020.03.299. PMID: 32272210

Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus. Curigliano G, Banerjee S, Cervantes Ruiperez A, Garassino M, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels J, Michielin O, Peters S, Tabernero J, Douillard J, Pentheroudakis G, all Voting Panel members. Annals of Oncology. 2020 Oct;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010. PMID: 32745693

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. Papaccio F, Rosello S, Huerta M, Gambardella V, Tarazona N, Fleitas T, Roda D, Cervantes A. Cancers. 2020 Dec 3;12(12):E3611. doi: 10.3390/cancers12123611. PMID: 33287114

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Rosello S, Pizzo C, Huerta M, Munoz E, Aliaga R, Vera A, Alfaro-Cervello C, Jorda E, Garces-Albir M, Roda D, Dorcaratto D, Tarazona N, Torondel S, Guijarro J, Sanchiz V, Gambardella V, Fleitas-Kanonnikoff T, Lluch P, Pascual I, Ferrandez A, Sabater L, Cervantes A. ESMO Open. 2020 Nov;5(6):e000929. doi: 10.1136/esmoopen-2020-000929. PMID: 33229503

New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: 10.1016/j.annonc.2020.07.012. PMID: 32710931

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G, Ikeda M, Lim H, Ho G, Choo S, Ren Z, Malhotra H, Ueno M, Ryoo B, Kiang T, Tai D, Vogel A, Cervantes Ruiperez A, Lu S, Yen C, Huang Y, Chen S, Hsu C, Shen Y, Tabernero J, Yen Y, Hsu C, Yoshino T, Douillard J. Annals of Oncology. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. PMID: 32067677

Personalized Medicine: Recent Progress in Cancer Therapy. Gambardella V, Tarazona Llavero N, Cejalvo Andujar J, Lombardi P, Huerta Alvaro M, Roselló Keränen S, Fleitas Kanonnikoff T, Roda Perez D, Cervantes Ruiperez A. Cancers. 2020 Apr 19;12(4):1009. doi: 10.3390/cancers12041009. PMID: 32325878

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA. British Journal of Cancer. 2020 Nov;123(11):1590-1598. doi: 10.1038/s41416-020-01041-x. PMID: 32913286

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. Gambardella V, Fleitas Kanonnikoff T, Tarazona Llavero N, Papaccio F, Huerta Alvaro M, Roselló Keränen S, Gimeno Valiente F, Roda Perez D, Cervantes Ruiperez A. Journal of Clinical Medicine. 2020 Sep 22;9(9):3049. doi: 10.3390/jcm9093049. PMID: 32971757

The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. Valentini V, Marijnen C, Beets G, Bujko K, De Bari B, Cervantes Ruiperez A, Chiloiro G, Coco C, Gambacorta M, Glynne-Jones R, Haustermans K, Meldolesi E, Peters F, Rodel C, Rutten H, van de Velde C, Aristei C. Radiotherapy and Oncology. 2020 Jan;142:6-16. doi: 10.1016/j.radonc.2019.07.001. PMID: 31431374

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). Bendell J, Sauri T, Cubillo Gracian A, Alvarez R, Lopez-Lopez C, Garcia-Alfonso P, Hussein M, Limon Miron M, Cervantes Ruiperez A, Montagut C, Santos Vivas C, Bessudo A, Plezia P, Moons V, Andel J, Bennouna J, van der Westhuizen A, Samuel L, Rossomanno S, Boetsch C, Lahr A, Franjkovic I, Heil F, Lechner K, Krieter O, Hurwitz H, McCAVE Study Grp. Oncologist. 2020 Mar;25(3):e451-e459. doi: 10.1634/theoncologist.2019-0291. PMID: 32162804

The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Gambardella V, Castillo Aliaga J, Tarazona Llavero N, Gimeno Valiente F, Martínez Ciarpaglini M, Cabeza Segura M, Roselló Keränen S, Roda Perez D, Huerta Alvaro M, Cervantes Ruiperez A, Fleitas Kanonnikoff T. Cancer Treatment Reviews. 2020 Jun;86:102015. doi: 10.1016/j.ctrv.2020.102015. PMID: 32248000

Trifluridine/Tipiracil in earlier lines of chemotherapy for advanced colorectal cancer. Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Sep;31(9):1097-1098. doi: 10.1016/j.annonc.2020.05.030. PMID: 32544547

Proyectos
Referencia: PI21/00689
Título: Caracterización y abordaje de la enfermedad mínima residual en cáncer de colon localizado: un paso hacia la medicina de precisión
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Noelia Tarazona Llavero, Andrés Cervantes Ruipérez
Duración: 2022 – 2024
Presupuesto: 232.320 €

Referencia: ICI20/00009
Título: Investigación Clínica Independiente
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2021 – 2024
Presupuesto: 1.039.970 €

Referencia: PT20/00100
Título: Plataforma de Investigación Clínica
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2021 – 2023
Presupuesto: 199.650 €

Referencia: 2020/111
Título: Tumor microenvironment-derived factors in localized colon cancer: clinical impact and therapeutic implications
Entidad Financiadora: Asociación Española Contra el Cáncer
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2020 – 2022
Presupuesto: 992.996 €

Referencia: 825832 – LEGACy
Título: CeLac and European consortium for a personalized medicine approach to Gastric Cancer
Entidad Financiadora: European Commission
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2019 – 2022
Presupuesto: €3.577.431,27 (INCLIVA: €638.315)

Referencia: PI18/01909
Título: Medicina personalizada en pacientes con cáncer colorrectal localizado: abordaje multiómico de la Enfermedad Mínima Residual en biopsia líquida y modelos de organoides
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez, Desamparados Roda
Duración: 2019 – 2021
Presupuesto: 141.570 €

Referencia: PT17/0017/0003
Título: Plataforma de Investigación y Ensayos Clínicos
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2018 – 2021
Presupuesto: 266.475 €

Referencia: CB16/12/00473
Título: CIBER Oncología (CIBERONC)
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2017 –
Presupuesto:

Referencia: AC15/00096
Título: Evolution of resistant clones to novel target-directed drugs in colorectal tumours. A genetic and apigenetic study of intratumoral herterogeneity dynamics
Entidad Financiadora: European Commission (Programación conjunta internacional ISCIII)
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2016 – 2020
Presupuesto: 29.645 €

+ Información
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. PMID: 35914638

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Vogel A, Martinelli E, ESMO Guidelines Commite. Annals of Oncology. 2021 Jun;32(6):801-805. doi: 10.1016/j.annonc.2021.02.014. PMID: 33716105

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti B, Ahn J, Faud I, Chee C, Yeh K, Lin P, Chua C, Hasbullah H, Lee M, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Annals of Oncology. 2021 Dec;32(12):1496-1510. doi: 10.1016/j.annonc.2021.08.1752. PMID: 34411693

New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: 10.1016/j.annonc.2020.07.012. PMID: 32710931

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G, Ikeda M, Lim H, Ho G, Choo S, Ren Z, Malhotra H, Ueno M, Ryoo B, Kiang T, Tai D, Vogel A, Cervantes Ruiperez A, Lu S, Yen C, Huang Y, Chen S, Hsu C, Shen Y, Tabernero J, Yen Y, Hsu C, Yoshino T, Douillard J. Annals of Oncology. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. PMID: 32067677

Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2019 Oct 1;30(10):1558-1571. doi: 10.1093/annonc/mdz233. PMID: 31378807

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018). Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Annals of Oncology. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510. PMID: 30715202

Título: Multi-omic characterization of advanced colorectal cancer patients derived organoids in the context of Precision Medicine
Doctorando: Papaccio, Federica
Director: Cervantes Ruipérez, Andrés; Castillo Aliaga, Josefa
Fecha: 23/12/2021
Universidad: Università della Campania Luigi Vanvitelli

Título: Genetic determinants of atr inhibitor sensitivity and resistance in gastric cancer
Doctorando: Llorca Cardeñosa, Marta Jessica
Director: Cervantes Ruipérez, Andrés; Ribas Despuig, Gloria
Fecha: 22/07/2019
Universidad: Universitat de València

Título: A multi-omic liquid biopsy-based signature as a valuable tool to assess minimal residual disease in localised colorectal cancer
Doctorando: Tarazona Llavero, Noelia
Director: Cervantes Ruipérez, Andrés
Fecha: 23/07/2019
Universidad: Universitat de València